After a challenging year, shares of biotech companies could see rebound following tax loss selling, Bret Jensen says.

Real Money's Bret Jensen outlines simple strategy to use with cancer drug maker.

Bristol-Myers Squibb shares climb after the drugmaker reports progress with a Phase 3 study of a lymphoma treatment.

These stocks that fell in the past week could be buy-the-dip opportunities. Recent losers include Okta, Match Group, Procter & Gamble, and more.

Bristol Myers Squibb agrees to pay Agenus up to $1.56 billion for the rights to its experimental immuno-cancer treatment.

Tesla CEO Musk discusses succession plans and Twitter with shareholders.

The company has made clear what it plans on the Las Vegas Strip, but it has a fast-approaching deadline.

Long-delayed futuristic looking electric vehicle will be in production by the middle of 2023